Teduglutide
Also known as: Gattex, Revestive, ALX-0600
Teduglutide is a long-acting GLP-2 analog for short bowel syndrome requiring parenteral support. Improved intestinal absorption can reduce IV nutrition/fluid dependence, with growth-related surveillance and fluid/obstruction risks.
Quick Facts
GLP-2 analog in intestinal failure
Teduglutide, developed as ALX-0600 and marketed as Gattex or Revestive in some regions, modifies the intestinal growth/repair hormone GLP-2. It addresses short bowel syndrome when removed or nonfunctioning intestine leaves insufficient nutrient/fluid absorption and dependence on IV support.
Intestinal adaptation and support reduction
One amino-acid change resists the enzyme that rapidly degrades natural GLP-2. Longer GLP-2-receptor activation increases villus height and crypt depth, expanding absorptive mucosa. In the pivotal program and extension, most continuing patients reduced parenteral support and a subset became independent. The same growth-promoting action makes colorectal polyp surveillance important.
Supporting references: reduced.
Sources: [1]
Who receives treatment
FDA approved teduglutide in 2012 for parenteral-support-dependent adult short bowel syndrome, later extending use to children aged 1 year or older. It is a once-daily subcutaneous treatment aimed at reducing dependence on parenteral nutrition or IV fluids. Colonoscopy is recommended before treatment and periodically afterward.
Supporting references: approved.
Sources: [2]
Growth, fluid and gastrointestinal concerns
Common effects include abdominal pain/distension, nausea/vomiting, upper respiratory infection, injection reactions, fluid overload and allergy. Serious concerns include colorectal polyp growth, intestinal obstruction, gallbladder/biliary/pancreatic problems and fluid overload. Surveillance and support adjustment belong to the clinical treatment context.
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- 10.1038/ctg.2015.69Intestinal adaptation and support reductionCited in: Intestinal adaptation and support reduction
- accessdata.fda.govWho receives treatmentCited in: Who receives treatment
Frequently Asked Questions About Teduglutide
Related Peptides
Continue exploring Teduglutide
Search all related references →Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.